|By PR Newswire||
|April 12, 2014 09:00 AM EDT||
LONDON, April 12, 2014 /PRNewswire/ --
Emerging biological drugs - discover R&D, business analysis, and revenue forecasts
What's the future of biologics, especially new drug classes? Now get the latest technological and commercial analysis. Staying ahead in data and knowledge, you benefit your authority. And you explore trends, developments, results, opportunities, and sales predictions.
So visiongain's new report shows you what's possible for biological drugs - their next phase. There avoid missing out. Instead find progress in that industry and market, discovering expected progress and revenues. See now how you can gain.
New biotechnological medicines will benefit patients and pharmaceutical companies. Read on to explore those therapies, hearing how high revenues can go.
Forecasting and other information showing the most lucrative possibilities for treatments
That study gives you sales forecasts to 2024 at overall world, submarket, product, and national level. See what the future holds, assessing gains for developers and producers.
Many opportunities exist. And besides giving revenue predictions, that new analysis shows recent results, growth rates, and market shares. There you discover 94 tables, 55 charts, and two interviews with authorities in the biopharmaceuticals sector.
And the following sections explain what our new investigation gives you.
Analyses exclusive to that study, showing the most important commercial potentials
In our report you get data found nowhere else. Discover what's really going on. Our forecasting system goes to the core of the biopharmaceutical industry's sales potential like no other work, giving revenue predictions and their meanings.
That analysis benefits your plans, decisions, and influence by interpreting medical needs, R&D, and companies' abilities. You hear what's happening, then, assessing likely gains.
So find in those analyses where potential and money lie, also saving time, worry, and effort.
Prospects for the world market and submarkets - what's possible for pharma biotechnology?
There, in our report, discover overall world sales to 2024 for biologics and new therapies, with discussions.
Also get individual revenue predictions to 2024 for 17 next-generation biologic submarkets at world level:
• Regenerative medicine, with submarket breakdowns for tissue engineering, stem cells, and gene therapies
• Antibodies, including monoclonal antibodies (mAbs), with sub-forecasting for antibody-drug conjugates (ADCs), engineered, and bispecific agents
• Antibody fragments and antibody-like protein (ALP) platforms
• Biosimilars (follow-on protein products).
To see a report overview please email Sara Peerun on [email protected]
And discover other segments' forecasts to 2024:
• Insulins, with submarkets for ultra-long acting, oral, and ultra-rapid-acting insulins
• Growth hormones
• Recombinant coagulation factors
• Other types of next-stage therapeutic proteins.
Next-generation biologics that treat new indications will be launched within 10 years. And you assess outlooks for that expansion in trade, hearing where you could gain.
Our study also explores competition. There you see what's happening for developers, producers, and sellers of new-generation biologics, understanding challenges, trends, and outlooks.
That work also splits its overall world market into leading products, showing where you could profit from new and improved biotech medicines.
Product forecasts for new forms, variations, and uses of biological therapy
How will individual drugs perform to 2024 at world level? Our report predicts revenues of seven top brands:
There you find products and years with highest forecasted sales. And the report predicts those seven therapies will earn combined revenue of more than $10bn in 2024.
You also examine competitors. See what's happening, then, understanding challenges, trends, competition, and opportunities. And here's what that study's author said:
"Next-generation biologics will address shortcomings in current therapies, including inconvenient dosing and concerns over side effects. Developmental trends include sustained release, for less-frequent dosing, and reformulations for oral and topical administration."
That work also gives geographical revenue forecasts.
Healthcare in national markets - what outlooks for business in new biopharma products?
Advances in biotechnology and healthcare expand use of novel biological drugs in developed and developing countries. Also opportunities exist for newer treatments.
And our analyses show you individual revenue forecasts to 2024 for nine national markets:
• United States (US)
• EU leaders - Germany, France, the UK, Italy, and Spain (EU5)
There you hear about the best sales potentials, appraising national opportunities for next-generation biologicals. See where and how you can profit.
For treating people and saving lives, you explore progress, needs, and possibilities. Find how pharma companies satisfy those demands, also assessing expected financial gains.
And what events influence the biologics industry? What's the outlook for tackling serious diseases? Our work shows you, discussing trends, challenges, and opportunities.
Market forces and issues - what affects biopharma developers, producers, and sellers?
The report explains trends, processes, and events affecting the biopharma industry and market from 2014, including these forces:
• Limitations of existing biologics
• Promise of next-generation biologics, and product launches
• Extension of half-life - pegylation and other technologies
• Demand rising for biological therapies
• Contract manufacturers (CMOs) serving those developmental needs and trends.
To see a report overview please email Sara Peerun on [email protected]
And you explore these influences, among others:
• Disease incidence affecting demand for those more-developed medicines
• Improvements in therapeutic antibodies, including targeted cytotoxic therapies
• R&D pipelines - e.g. for immunotoxins - including agents in clinical development
• Biosimilar insulins likely from 2015 - transformation of that market
• Effects of rising incidence rates in cancer, diabetes, and cardiovascular disorders.
There discover what the future holds. You explore political, economic, social, and technological questions. See too how R&D helps companies benefit patients.
So you explore what progress, trends, and prospects mean. And discover what helps and what hinders players in that healthcare industry, affecting participants' results.
Biological drug technology and applications - companies and 2018 market value
So what happens next? From 2014, novel and biosimilar treatments will benefit patients, doctors, and payers. Those advances will encourage investments, medical progress, and higher revenues from more-advanced biological drugs.
And our study predicts the next-generation biologics market will reach $12.17bn worldwide in 2018, and then multiply in revenues to 2024. See what's possible and what you can gain.
That work also explores activities of these leading companies, among many other firms:
• Eli Lilly
• Novo Nordisk
• Kyowa Hakko Kirin
• Baxter International.
In that market, large pharmaceutical corporations and smaller biopharma specialists can win. See how.
And you find 235 organisations covered. You also get interviews with two companies in the industry, helping you stay ahead. See, then, what the future holds.
Ways Next-Generation Biologics: R&D, Industry and Market 2014-2024 helps
In three main ways our new investigation helps you gain recognition for insight, with data found only there:
• Revenues to 2024 at world level, for 17 submarkets, and 7 products - explore outlooks for production, marketing, and sales
• Forecasts to 2024 for 9 national markets in North America, Europe, and Asia - assess countries for revenues and sales expansions
• Prospects for established competitors, rising companies, and new entrants - investigate portfolios, results, strategies, R&D, and opinions from interviews.
Knowledge there found nowhere else, helping your searches, analyses, and planning
Our new report provides competitive intelligence, showing where progress and money lie.
That work's purpose is to predict sales results with maximum clarity, applicability, and detail. And its research and analyses identify and explain commercial prospects. Now you explore the biological drug industry's future through data exclusive to that study.
So our analysis helps you avoid falling behind in information or missing opportunity. Also it lets you save time and effort. And now your choice could benefit your plans, decisions, and authority - increasing your chances of finding competitive advantages.
Biopharmaceutical knowledge - getting our new report now helps you stay ahead
By trying our new study on emerging biologicals you explore trends, R&D, and sales predictions. There stay ahead - please get that report here now.
To request a report overview please email Sara Peerun at [email protected] or call Tel : +44 (0) 20 7336 6100
Companies Listed in this report:
Adnexus (part of Bristol-Myers Squibb)
Advanced Cell Technology
Agence Nationale de sécurité du Médicament et des produits de santé (ANSM)
Alcon (part of Novartis)
Alfacell (now Tamir Biotechnology)
Applied Genetic Technologies (AGTC)
Biopartners (part of Bioton)
BioVex Group (part of Amgen)
BioWa (part of Kyowa Hakko Kirin)
BrainStorm Cell Therapeutics
Catalent Pharma Solutions
Cellular Dynamics International (CDI)
Centers for Disease Prevention and Control (CDC) [US]
Cephalon (part of Teva)
CEPiA (part of Sanofi)
Children's Hospital of Philadelphia (CHOP)
China Food and Drug Administration (CFDA)
Chugai (part of Roche)
Depuy Mitek (part of J&J)
Dr. Reddy's Laboratories
Duke University Hospital
Elan Pharmaceuticals (now part of Perrigo Company)
EMA's Committee for Medicinal Products for Human Use (CHMP)
Epitomics (part of Abcam)
ESBATech (part of Novartis)
European Medicines Agency (EMA)
Food and Drug Administration (FDA) [US]
Fresenius Biotech (now named Neovii Biotech, part of Neopharm)
Fujifilm Diosynth Biotechnologies
Genentech (part of Roche)
Genzyme (part of Sanofi)
Human Stem Cells Institute (HSCI)
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Germany]
International Diabetes Federation (IDF)
Kyowa Hakko Kirin
LG Life Sciences
MedImmune (part of AstraZeneca)
Merck & Co.
Micromet (part of Amgen)
Ministry of Health, Labor and Welfare (MHLW) [Japan]
Mitsubishi Tanabe Pharma
Moorfields Eye Hospital [UK]
National Cancer Institute (NCI) [US]
National Health Service (NHS) [UK]
National Institute for Health and Care Excellence (NICE) [UK]
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [US]
Prolor Biotech (part of OPKO Health)
ratiopharm (part of Teva)
Reliance Life Sciences
Roche Glycart (part of Roche)
Royal Institute of Technology [Sweden]
Russian Ministry of Healthcare (Minzdrav)
Sandoz (part of Novartis)
Scottish Medicines Consortium (SMC)
Shanghai Sunway Biotech
Shenzhen SiBiono GeneTech (part of Benda)
Shreya Life Sciences
Spirogen (part of AstraZeneca)
Stelis Biopharmaceuticals (part of Strides Arcolab)
Swedish Orphan Biovitrum (Sobi)
Swiss Federal Institute of Technology
Synthon Biopharmaceuticals (part of Synthon)
Takeda Pharmaceutical Company
Teva Pharmaceutical Industries
Tianjin International Joint Academy of Bio-medicine
University of Toronto
University of California, San Francisco (UCSF)
World Bank Group
World Cancer Research Fund (WCRF)
World Health Organization (WHO)
Wyeth (part of Pfizer)
Yale School of Medicine
To see a report overview please email Sara Peerun on [email protected]
Too often with compelling new technologies market participants become overly enamored with that attractiveness of the technology and neglect underlying business drivers. This tendency, what some call the “newest shiny object syndrome,” is understandable given that virtually all of us are heavily engaged in technology. But it is also mistaken. Without concrete business cases driving its deployment, IoT, like many other technologies before it, will fade into obscurity.
Sep. 3, 2015 04:30 PM EDT Reads: 427
All major researchers estimate there will be tens of billions devices - computers, smartphones, tablets, and sensors - connected to the Internet by 2020. This number will continue to grow at a rapid pace for the next several decades. With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo, November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Learn what is going on, contribute to the discussions, and e...
Sep. 3, 2015 04:15 PM EDT
Puppet Labs is pleased to share the findings from our 2015 State of DevOps Survey. We have deepened our understanding of how DevOps enables IT performance and organizational performance, based on responses from more than 20,000 technical professionals we’ve surveyed over the past four years. The 2015 State of DevOps Report reveals high-performing IT organizations deploy 30x more frequently with 200x shorter lead times. They have 60x fewer failures and recover 168x faster
Sep. 3, 2015 04:15 PM EDT
To support developers and operations professionals in their push to implement DevOps principles for their infrastructure environments, ProfitBricks, a provider of cloud infrastructure, is adding support for DevOps tools Ansible and Chef. Ansible is a platform for configuring and managing data center infrastructure that combines multi-node software deployment, ad hoc task execution, and configuration management, and is used by DevOps professionals as they use its playbooks functionality to autom...
Sep. 3, 2015 04:15 PM EDT
Containers are not new, but renewed commitments to performance, flexibility, and agility have propelled them to the top of the agenda today. By working without the need for virtualization and its overhead, containers are seen as the perfect way to deploy apps and services across multiple clouds. Containers can handle anything from file types to operating systems and services, including microservices. What are microservices? Unlike what the name implies, microservices are not necessarily small,...
Sep. 3, 2015 04:00 PM EDT Reads: 138
Whether you like it or not, DevOps is on track for a remarkable alliance with security. The SEC didn’t approve the merger. And your boss hasn’t heard anything about it. Yet, this unruly triumvirate will soon dominate and deliver DevSecOps faster, cheaper, better, and on an unprecedented scale. In his session at DevOps Summit, Frank Bunger, VP of Customer Success at ScriptRock, will discuss how this cathartic moment will propel the DevOps movement from such stuff as dreams are made on to a prac...
Sep. 3, 2015 04:00 PM EDT Reads: 258
ElasticBox, the agile application delivery manager, announced freely available public boxes for the DevOps community. ElasticBox works with enterprises to help them deploy any application to any cloud. Public boxes are curated reference boxes that represent some of the most popular applications and tools for orchestrating deployments at scale. Boxes are an adaptive way to represent reusable infrastructure as components of code. Boxes contain scripts, variables, and metadata to automate proces...
Sep. 3, 2015 03:30 PM EDT
The 3rd International WebRTC Summit, to be held Nov. 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA, announces that its Call for Papers is now open. Topics include all aspects of improving IT delivery by eliminating waste through automated business models leveraging cloud technologies. WebRTC Summit is co-located with 15th International Cloud Expo, 6th International Big Data Expo, 3rd International DevOps Summit and 2nd Internet of @ThingsExpo. WebRTC (Web-based Real-Time Com...
Sep. 3, 2015 03:00 PM EDT Reads: 1,604
As more and more data is generated from a variety of connected devices, the need to get insights from this data and predict future behavior and trends is increasingly essential for businesses. Real-time stream processing is needed in a variety of different industries such as Manufacturing, Oil and Gas, Automobile, Finance, Online Retail, Smart Grids, and Healthcare. Azure Stream Analytics is a fully managed distributed stream computation service that provides low latency, scalable processing of ...
Sep. 3, 2015 02:45 PM EDT Reads: 385
SYS-CON Events announced today that DataClear Inc. will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. The DataClear ‘BlackBox’ is the only solution that moves your PC, browsing and data out of the United States and away from prying (and spying) eyes. Its solution automatically builds you a clean, on-demand, virus free, new virtual cloud based PC outside of the United States, and wipes it clean...
Sep. 3, 2015 02:45 PM EDT Reads: 477
In 2014, the market witnessed a massive migration to the cloud as enterprises finally overcame their fears of the cloud’s viability, security, etc. Over the past 18 months, AWS, Google and Microsoft have waged an ongoing battle through a wave of price cuts and new features. For IT executives, sorting through all the noise to make the best cloud investment decisions has become daunting. Enterprises can and are moving away from a "one size fits all" cloud approach. The new competitive field has ...
Sep. 3, 2015 02:45 PM EDT Reads: 172
SYS-CON Events announced today that HPM Networks will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. For 20 years, HPM Networks has been integrating technology solutions that solve complex business challenges. HPM Networks has designed solutions for both SMB and enterprise customers throughout the San Francisco Bay Area.
Sep. 3, 2015 02:30 PM EDT Reads: 962
With the proliferation of connected devices underpinning new Internet of Things systems, Brandon Schulz, Director of Luxoft IoT – Retail, will be looking at the transformation of the retail customer experience in brick and mortar stores in his session at @ThingsExpo. Questions he will address include: Will beacons drop to the wayside like QR codes, or be a proximity-based profit driver? How will the customer experience change in stores of all types when everything can be instrumented and a...
Sep. 3, 2015 02:30 PM EDT Reads: 509
SYS-CON Events announced today the Containers & Microservices Bootcamp, being held November 3-4, 2015, in conjunction with 17th Cloud Expo, @ThingsExpo, and @DevOpsSummit at the Santa Clara Convention Center in Santa Clara, CA. This is your chance to get started with the latest technology in the industry. Combined with real-world scenarios and use cases, the Containers and Microservices Bootcamp, led by Janakiram MSV, a Microsoft Regional Director, will include presentations as well as hands-on...
Sep. 3, 2015 02:15 PM EDT Reads: 413
Moving an existing on-premise infrastructure into the cloud can be a complex and daunting proposition. It is critical to understand the benefits as well as the challenges associated with either a full or hybrid approach. In his session at 17th Cloud Expo, Richard Weiss, Principal Consultant at Pythian, will present a roadmap that can be leveraged by any organization to plan, analyze, evaluate and execute on a cloud migration solution. He will review the five major cloud transformation phases a...
Sep. 3, 2015 01:45 PM EDT